Studying ctDNA changes after radiation for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial studies how radiation therapy (SBRT) affects a DNA fragment in the blood called ctDNA in people with liver cancer. By tracking ctDNA changes, doctors hope to better understand how well the treatment is working and possibly predict outcomes earlier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have liver cancer (hepatocellular carcinoma) with a tumor at least 3 cm in size
- You are planning to have a precise radiation treatment called SBRT
- Your liver is working fairly well (Child-Pugh A level)
- Your blood counts and kidney function are within safe ranges for the study
- You have not had TACE (a type of liver-directed therapy) in the last 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy and high-precision radiation (SBRT) to shrink large or multiple liver tumors in people with hepatocellular carcinoma, with the goal of making them small enough for surgery. It's for people who cannot currently have their tumors removed but might become eligible after treatment.
This trial tests a combination of radiation therapy, an immunotherapy drug (tislelizumab), and a targeted therapy drug (anlotinib) for people with liver cancer that has spread into the main blood vessel of the liver (portal vein). The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).
This trial tests whether a targeted radiation therapy (SBRT) can help people with liver cancer whose disease has only a few new spots growing while on first-line immunotherapy. It aims to see if zapping those spots can control the cancer and delay the need for stronger treatments.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
This trial is testing whether giving focused radiation therapy (SBRT) after liver surgery helps lower the chance of cancer coming back. It is for people whose surgery left a very small safety margin around the tumor.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.